Hu3F8-BsAb (humanized 3F8 bispecific antibody)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Hu3F8-BsAb (humanized 3F8 bispecific antibody), covering 2023-06-22 to 2023-06-22. Get the full timeline:
Most recent: Clinical Trial Update: Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers [Phase 1, Phase 2]